- Get Off the Couch: Another Study Shows Sitting’s Health Dangers
- Falling Vaccination Rates Brings Spikes in Measles Worldwide
- Nearly 260 Million Americans Could Be Overweight or Obese by 2050
- Over 40? Get Fitter and Live 5 Extra Years
- Can AI Boost Accuracy of Doctors’ Diagnoses?
- More Evidence That GLP-1 Meds Curb Alcohol Abuse
- Breathing Dirty Air Might Raise Eczema Risks
- Chlamydia Vaccine Shows Early Promise in Mice
- Stop Worrying So Much About Holiday Weight Gain, Experts Say
- Trump Picks Vaccine Skeptic Robert F. Kennedy Jr. to Lead Health & Human Services
Fecal Transplant Treats Serious, Recurrent Intestinal Infection
Fecal transplants, using stool from a donor, have been successful at treating a serious gut infection, researchers report.
The infection is called Clostridium difficile. It causes diarrhea and severe abdominal pain and kills thousands of people worldwide each year, the authors of the small study explained. It’s believed that the infection overwhelms the good bacteria required to maintain a healthy intestine.
The fecal transplant method was developed to treat people with C. difficile infections, particularly those who have repeat infections. Fecal matter is collected from a donor, purified, mixed with a saline solution and transferred to the patient, usually by colonoscopy.
However, not much is known about the long-term stability of fecal transplants, the University of Minnesota researchers pointed out.
The study, published in the current issue of the journal Microbiome, included 14 people who had recurring C. difficile infections. Four received fecal transplants.
The healthy changes in the patients’ intestinal bacterial populations (“microbiome”) were sustained for up to 21 weeks after transplant, according to the report.
“Our study shows that there are both short- and long-term changes in the fecal microbiome following transplantation,” study author Michael Sadowsky, director of the university’s BioTechnology Institute, said in the news release.
“The diversity and types of microbes present fall into a cloud of possibilities represented by those of ‘normal fecal microbiota.’ While we have many similarities in fecal microbiota amongst humans in general, there are individual differences that make us all unique, but do not affect apparent gut functioning,” he explained.
The study could have implications for the regulation of fecal transplants in the United States, the authors suggested. The U.S. Food and Drug Administration considers fecal transplants to be a drug and has said standardization will be important.
However, the diversity of normal fecal bacteria in both donors and recipients suggests that this approach to regulation will not work for fecal transplants, the investigators said in the news release.
More information
The Fecal Transplant Foundation has more about fecal transplantation.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.